The OxyContin maker filed its long-awaited restructuring plan in bankruptcy court. Revenue from the new company would go exclusively to abating the opioid crisis.
Published: March 16, 2021 at 05:11AM
from NYT Health https://ift.tt/3cAb56i
The OxyContin maker filed its long-awaited restructuring plan in bankruptcy court. Revenue from the new company would go exclusively to abating the opioid crisis.
Published: March 16, 2021 at 05:11AM
from NYT Health https://ift.tt/3cAb56i
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)